Wed, Sep 17, 2014, 2:04 AM EDT - U.S. Markets open in 7 hrs 26 mins


% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

  • bob_flemings bob_flemings Oct 22, 2013 9:35 AM Flag

    apples to oranges

    NeoStem has been at the center of a storm surrounding the results of a CADUCEUS study. The study noted that stem cell treatment was "safe and effective in decreasing scar size and in increasing viable tissue," but "did not lead to any significant changes from baseline to 1 year in end-diastolic and end-systolic volumes, cardiac output, or stroke volume - which also was evident at 6 months."

    A post seen on Seeking Alpha ran with this statement and painted all stem cells with the same brush, which is a far cry from the truth. The CADUCEUS trial used cardiosphere-derived stem cells or CDCs, whereas AMR-001 uses stem cells derived from bone marrow, a disparity that NeoStem CEO, Robin Smith, likened to "comparing apples and oranges.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
5.35-0.02(-0.37%)Sep 16 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.